FSA/HSA & CareCredit!
Think of peptides as tiny chemical messengers. They’re just short chains of amino acids—the building blocks of proteins—but what they do is surprisingly powerful. These little guys float around your body telling your cells what to do: “Hey, heal that wound.” “Fix that energy issue.” “Reduce that inflammation.”
Over the past decade, researchers have started isolating and studying specific peptides that seem to have some pretty remarkable effects. Four of them have gotten particular attention:
- BPC-157 — The “healing peptide” that shows promise for tissue repair
- MOTs-c — The “mitochondrial peptide” that helps your cells’ power plants run better
- NAD+ & NMN — The “energy and longevity” peptides that address a key feature of aging
- Reta — The cutting-edge “triple hormone agonist” showing unprecedented results in weight loss and metabolic health
So what’s the real story? What do the studies actually show? And what are people getting wrong? Let’s dig in.
Dr. Sende Wellness: Miami’s Premier Peptide Therapy Center
While the research on peptides continues to advance globally, Miami has become a hub for personalized peptide therapy. Dr. Fernando Sende Wellness, located in the heart of Miami, offers comprehensive peptide treatments for patients seeking evidence-based, customized health solutions.
Who is Dr. Fernando Sende?
Dr. Fernando Sende is a double board-certified physician specializing in cardiology and internal medicine. His expertise in metabolic health and personalized medicine makes him uniquely qualified to assess individual peptide therapy needs and monitor patient outcomes. Dr. Sende’s approach integrates advanced peptide protocols with comprehensive medical evaluation, laboratory testing, and ongoing monitoring to ensure safety and efficacy.
Comprehensive Peptide Services
Dr. Sende Wellness offers an extensive range of peptide therapies categorized by therapeutic application:
- Reta (Triple Hormone Agonist): Next-generation therapy targeting GLP-1, GIP, and glucagon pathways for superior weight loss and metabolic optimization
- Growth Hormone & Anti-Aging Peptides: CJC-1295, Ipamorelin, Sermorelin, Hexarelin, and others for muscle growth, fat loss, and anti-aging benefits
- Dual GLP-1/GIP Agonists: Advanced metabolic optimization therapies
- Healing & Recovery Peptides: BPC-157, TB-500, and GHK-Cu for tissue repair and recovery optimization
- Cognitive Enhancement Peptides: Semax, Selank, and Dihexa for focus, memory, and neuroprotection
- Immune Support Peptides: Thymosin Alpha-1 and immune-modulating peptides
- Gut Health Peptides: KPV and Larazotide for gastrointestinal wellness
- Sexual Health & Hormonal Peptides: PT-141 and specialized formulations
- Cardiovascular & Mitochondrial Peptides: SS-31, MOTS-c, Humanin, and NAD+ support
- Muscle Building & Joint Health Peptides: IGF-1 variants, Follistatin, and joint-supporting compounds
Treatment Approach
Dr. Sende’s methodology emphasizes personalization. Rather than one-size-fits-all peptide protocols, he conducts:
- Detailed health history and functional assessment
- Comprehensive laboratory testing to identify specific deficiencies or imbalances
- Customized peptide protocol design based on individual health goals and conditions
- Ongoing monitoring and protocol adjustments for optimal results
- Integration with nutrition and lifestyle guidance through complimentary nutritionist consultations
Access & Convenience
Dr. Sende Wellness provides both in-office and telemedicine appointments, making peptide therapy accessible whether you’re in Miami or elsewhere. The practice is located at 1063 SW Eighth Street, Miami, FL 33130 and serves Miami-Dade and Broward County areas. Door delivery is available in the Miami/Broward region.
Contact & Consultation
To schedule a consultation for personalized peptide therapy:
- Phone: (786) 655-0187
- Email: office@drsende.com
- Book Online: Schedule a Free Initial Consultation
- Hours: Monday-Friday: 12pm-5pm (After Hours & Weekends by appointment)
Visit DrSende.com to learn more about peptide therapy options and explore all available services.
BPC-157: The Peptide Everyone in Miami is Talking About
If you’ve scrolled through fitness or wellness forums, you’ve probably heard someone mention BPC-157. It’s become something of a legend in recovery communities. But where did it come from? And what does the science actually say?
BPC-157: The Basics
BPC-157 stands for Body Protection Compound-157. It’s a short peptide made of just 15 amino acids, and it was originally discovered in your stomach’s protective juices. Researchers noticed it seemed to have some serious healing properties, so they started studying it. A lot.
What Does the Research Show?
Here’s where it gets interesting. In 2025, researchers did something ambitious—they looked at every BPC-157 study they could find going back 30+ years. We’re talking 544 articles analyzed. What they found was pretty consistent:
The Bottom Line: In rats and mice, BPC-157 consistently helped tissues heal. It did this by boosting growth factors, reducing inflammation, and encouraging new blood vessel formation. The peptide worked on tendons, ligaments, muscles, and even bones. The good news? Researchers saw improved healing in virtually every tissue type they tested. The catch? Almost all of this data comes from animals, not humans.
How Does It Actually Work?
BPC-157 doesn’t just magically heal tissues. It works through specific biological pathways. Here’s what’s happening under the hood:
- New Blood Vessels: BPC-157 tells your body to build new blood vessels at the injury site. More blood = more nutrients and oxygen for healing.
- Growth Factors: It ramps up growth-promoting proteins that signal cells to repair and rebuild.
- Reduces Inflammation: While some inflammation is good (it’s part of healing), BPC-157 seems to dial down excessive inflammation that gets in the way.
- Gut Protection: Its original discovery was in stomach lining, so it shows protective effects in the GI tract too.
- Brain Effects: Early research suggests it might interact with dopamine and serotonin, but this is still being studied.
But What About Humans?
While animal studies are promising, human trials are beginning to emerge. Recent reviews have documented three published human studies:
- Study 1: A Phase II trial for ulcerative colitis that showed benefit and demonstrated safety
- Study 2: 12 people received BPC-157 injected into their knee for pain with reported improvement
- Study 3: 2 healthy people received IV BPC-157 with no adverse effects reported
The transition from preclinical to clinical research continues to expand our understanding of BPC-157’s potential in human subjects.
The Regulatory Status
BPC-157 is not FDA-approved for therapeutic use in the United States. The FDA has classified it as not approvable for commercial pharmaceutical development. It is also banned by sports authorities like WADA (World Anti-Doping Agency).
Research-grade BPC-157 is available through legitimate scientific suppliers for investigational purposes. Quality standards and purity specifications vary across suppliers, which is why sourcing from established research suppliers is important.
As research continues to accumulate, the regulatory pathway for BPC-157 may evolve based on clinical trial data and safety findings.
MOTs-c: Your Cells’ Cellular Energy Crisis
Remember when we used to joke about “getting old” and being “too tired”? Scientists have a name for that now: mitochondrial dysfunction. And they found a peptide that might actually help with it.
MOTs-c: The Cellular Power Plant Manager
MOTs-c is a tiny 16-amino acid peptide that your mitochondria actually make themselves. Think of mitochondria as your cells’ power plants. MOTs-c is like the factory manager that tells the power plant how to run more efficiently. It was discovered in 2015, and researchers have been excited about it ever since.
What Happens When MOTs-c Drops?
Here’s the problem: MOTs-c levels go down as you age. This is huge because MOTs-c is one of the main ways your cells regulate metabolism and energy production.
Lower MOTs-c = tired cells = aging bodies. It’s linked to diabetes, obesity, and age-related diseases. So what if you could boost it?
What the Recent Research Shows
2025 Breakthrough: A recent study published in Frontiers in Physiology found that when you give MOTs-c to diabetic rats, their cells’ power plants (mitochondria) actually work better. The treated rats also didn’t gain as much weight compared to untreated rats. This matters because it suggests MOTs-c could help with the metabolic dysfunction that comes with diabetes.
The Aging Connection
Here’s something really interesting: recent research from 2025 shows that MOTs-c levels drop as you get older, especially in people with diabetes. Researchers gave MOTs-c to aging mice, and the mice’s pancreases actually functioned better. Their cells aged slower. That’s a big deal.
This opens a weird chicken-and-egg question: Does low MOTs-c cause aging, or does aging cause low MOTs-c? Scientists are still figuring that out.
The Exercise Connection
An important finding in the literature: when you exercise, your body actually makes more MOTs-c. That’s why it’s sometimes called an “exercise mimetic”—it’s what your body produces when you work out. Research suggests MOTs-c may be a key molecular response to physical activity.
This exercise-induced elevation of MOTs-c has garnered significant interest among researchers studying metabolic adaptation and aging.
Clinical Development Status
MOTs-c remains in active preclinical and early clinical research phases. The peptide has been banned by WADA and is not yet approved by the FDA or other regulatory agencies. However, clinical interest continues to grow, with several research programs exploring its therapeutic potential in metabolic disorders.
NAD+ & NMN: The Energy Story
This is where the story changes. Unlike BPC-157 and MOTs-c, NAD+ and its precursor NMN have actually made it to human clinical trials. And we have real results to talk about.
The Basic Energy Problem
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme—basically a helper molecule—that your cells need to produce energy. NMN (Nicotinamide Mononucleotide) is the immediate precursor your body uses to make NAD+. You can take NMN as a supplement, and your body converts it to NAD+.
Here’s the problem: NAD+ levels drop dramatically as you age.
The Aging-Energy Connection
By middle age, NAD+ levels have dropped to about half what they were in youth. This matters because NAD+ is involved in energy production, DNA repair, cell signaling, mitochondrial function and more. When NAD+ declines, these cellular functions are compromised.
This understanding has led researchers to investigate whether restoring NAD+ levels through NMN supplementation could support metabolic health and healthy aging.
What Actually Happened in Human Studies?
This is the good news: unlike BPC-157 and MOTs-c, NMN has actually been tested in humans and the results have been published. Here’s what researchers found:
Real Human Results:
- Older Adults Got Faster: In a 2024 study, healthy people over 65 took 250 mg of NMN daily for 12 weeks. They walked faster (measured in a 4-meter walking test) and reported better sleep quality. Their blood NAD+ levels went up.
- Multiple Trials Show Consistent Patterns: When researchers looked at data from 9 different studies involving 412 people, they found NMN consistently improved walking speed and muscle mass.
- It’s Safe: Even long-term studies (over 8 weeks) in healthy middle-aged adults showed no major safety issues with 250 mg daily.
So we have actual human evidence that NMN works—to a point. People got measurably faster and stronger. But here’s the honest part: the improvements were modest, and we don’t have huge long-term studies yet.
How NAD+ Actually Works
Research from 2025 breaks down NAD+’s role in your body:
- Energy Production: NAD+ is required to make ATP—the energy currency your cells use for all functions.
- DNA Repair: When your DNA gets damaged, NAD+ helps repair it.
- Cell Signaling: NAD+ powers enzymes called sirtuins, which regulate cellular health and aging-related processes.
- Mitochondrial Health: NAD+ keeps your mitochondria running efficiently.
- Inflammation Control: NAD+ helps regulate inflammatory pathways and maintain immune homeostasis.
NMN vs. Other NAD+ Boosters
Several NAD+ precursors exist with different bioavailability profiles: NR (Nicotinamide Riboside), NAM (nicotinamide), and niacin. According to a 2025 roundtable of NAD+ experts, here’s what the research shows:
- NMN and NR are comparable: Both effectively boost NAD+ levels, though they utilize different cellular transport mechanisms.
- Sex-specific differences observed: NMN demonstrated benefits in women (improved insulin sensitivity), while NR response varies by study design and population.
- Dosage optimization: Research studies utilize 250-2000 mg/day doses, with optimal dosing depending on the specific health parameter being measured.
- Alternative precursors: Niacin and other precursors have distinct pharmacological profiles and effects on NAD+ metabolism.
NMN represents one of the more extensively studied NAD+ precursors in human clinical trials, with the most comprehensive safety and efficacy data available.
Reta: The Next Frontier in Peptide Therapy
As peptide research advances, a groundbreaking new category of therapeutics has emerged: Reta, a triple hormone receptor agonist that simultaneously targets three distinct metabolic pathways. Rather than mimicking one or two hormones like current GLP-1 or GLP-1/GIP therapies, Reta activates three complementary receptor systems simultaneously.
How Reta Works: Triple Hormone Mechanism
Reta targets GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This simultaneous three-pathway activation creates a synergistic effect that appears to exceed the results seen with dual-pathway therapies:
- GLP-1 Activity: Reduces appetite and increases satiety
- GIP Activity: Enhances glucose-dependent insulin secretion and metabolic flexibility
- Glucagon Activity: Increases energy expenditure and metabolic rate
Reta Clinical Trial Results
Recent meta-analysis of Reta trials shows remarkable efficacy in weight loss and metabolic improvement. In phase 2 studies, patients achieved up to 24.2% mean weight reduction after 48 weeks of treatment—substantially higher than previously seen with dual-pathway therapies.
Reta Key Clinical Data:
- Weight Loss: 24.2% mean weight reduction at 48 weeks with the highest dose, with over 90% of participants achieving 10% or greater weight loss
- Metabolic Control: HbA1c improved by 2.2%, with 82% of type 2 diabetic participants reaching HbA1c ≤ 6.5%
- Cardiometabolic Benefits: Improvements in waist circumference, blood pressure, and lipid profiles
- Rapid Results: Significant weight loss achieved in 24 weeks—faster than competing therapies
- Glycemic Reversal: 72% of prediabetic participants reverted to normal blood sugar levels
Recent Phase 3 Data
The most recent phase 3 trial (TRIUMPH-4) in adults with obesity and knee osteoarthritis showed 28.7% mean weight loss at the highest dose, along with substantial improvements in joint pain and physical function. Additional phase 3 trials are ongoing to evaluate cardiovascular and renal outcomes.
Reta vs. Current Weight Loss Medications
When compared with currently available obesity medications, Reta shows superior weight loss outcomes. To provide context:
- Semaglutide (2.4 mg): ~7.2% weight loss in clinical trials
- Tirzepatide (15 mg): ~12% weight loss over 68-72 weeks
- Reta (highest dose): Up to 24.2% weight reduction in just 48 weeks
Reta Safety and Tolerability
The safety profile of Reta is generally favorable, with gastrointestinal side effects (nausea, diarrhea, constipation) being the most commonly reported adverse events. These side effects align with what’s observed with current GLP-1 and GLP-1/GIP therapies. The discontinuation rate due to adverse events is comparable to or slightly higher than dual-therapy options.
Reta for Type 2 Diabetes
Beyond weight loss, Reta shows exceptional promise in type 2 diabetes management. In patients with type 2 diabetes, Reta achieved 16.9% mean weight reduction and improved HbA1c by 2.2% after 36 weeks, with 82% of participants reaching HbA1c levels ≤ 6.5%.
In phase 2 obesity trials, 72% of participants with prediabetes at baseline reverted to normoglycemia with Reta treatment. This represents a significant finding: Reta not only treats existing diabetes but can prevent progression from prediabetes to type 2 diabetes in a substantial portion of patients.
Reta’s Cardiometabolic Benefits
Beyond weight loss, Reta improves multiple cardiometabolic parameters including systolic blood pressure reductions and improvements in lipid profiles. Recent phase 3 data showed Reta reduced non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein (a marker of inflammation).
Reta Phase 3 Trial Program
Multiple phase 3 trials are currently underway evaluating Reta across different populations. These include studies in patients with obesity, type 2 diabetes, obesity with joint disease, chronic kidney disease, and atherosclerotic cardiovascular disease. Seven additional phase 3 readouts are expected in 2026, evaluating different dose ranges including a maintenance dose of 4 mg in addition to higher therapeutic doses.
Clinical Significance of Reta
Reta represents a paradigm shift in obesity and metabolic disease management, offering patients superior weight loss, improved glycemic control, and cardiometabolic benefits in a single once-weekly injection. This approach is particularly promising for patients who have not adequately responded to existing GLP-1 or GLP-1/GIP therapies.
Reta: Regulatory Status and Timeline
Reta is currently in advanced clinical development. A 2027 FDA approval is predicted by industry analysts, with 2031 sales forecasts of approximately $15.6 billion, reflecting expectations that Reta could become one of the most important medications for metabolic disease management.
Clinical trials are currently recruiting participants to evaluate Reta’s safety and efficacy across multiple conditions including obesity with type 2 diabetes, chronic kidney disease, and cardiovascular disease. These ongoing studies will provide critical information about long-term benefits and safety profiles in diverse patient populations.
Development Stage Overview
These peptides are at different stages of clinical investigation:
Research Maturity Comparison:
- NMN/NAD+ Precursors: Published human clinical trials demonstrating measurable improvements in physical performance metrics, muscle composition, and metabolic markers. Comprehensive safety data. Available through dietary supplement channels.
- BPC-157: Extensive preclinical research foundation (540+ publications). Emerging human clinical investigations. Research-grade availability for investigational purposes.
- MOTs-c: Growing preclinical evidence base. Multiple active clinical research programs. Early-stage investigational development.
- Reta (Triple Hormone Agonist): Advanced phase 3 clinical trials across multiple conditions. Published phase 2 data in major journals. Expected FDA review beginning 2026. Clinical trial recruitment ongoing.
Regulatory Pathways
The regulatory status reflects the stage of clinical development:
- NMN: Classified as dietary supplement with ongoing clinical research programs. More established regulatory framework.
- BPC-157 & MOTs-c: Subject to sports doping regulations. Research-grade availability. Clinical development continues through investigational pathways.
Scientific Sources & Further Reading
The following peer-reviewed sources form the foundation of this article’s claims. All links point to open-access or official scientific databases.
BPC-157 Research
Comprehensive systematic review analyzing 544 articles on BPC-157, covering mechanism of action, musculoskeletal effects, metabolism, and safety profile. Published in the journal Orthopaedic Surgery.
Review of BPC-157’s pleiotropic effects and possible relations with neurotransmitter activity. Published in Biomedicines.
Scoping review evaluating molecular mechanisms, therapeutic potential, and safety concerns of BPC-157.
Review of BPC-157 Peptide & Patent Literature (2025)
MDPI comprehensive review summarizing biological activities, mechanism of action, and patent applications for BPC-157.
MOTs-c Research
Recent study demonstrating MOTS-c’s effects on mitochondrial function in diabetic models. Published in Frontiers in Physiology.
Comprehensive review of MOTS-c’s mechanisms and therapeutic potentials in aging, cardiovascular disease, and metabolic disorders.
2025 Study – “Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence”
Recent research showing MOTS-c’s role in reducing pancreatic β-cell senescence in aging and diabetes models. Published in Experimental & Molecular Medicine.
2024 Study – “Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression”
Advanced Science research exploring MOTS-c in cancer biology and its potential therapeutic implications.
NAD+ and NMN Research
Comprehensive List of Completed NMN Human Trials
Updated database of all published human clinical trials examining NMN supplementation, with results and methodology details.
Recent comprehensive review comparing NAD+ precursors and their effects on metabolism and health. Published in Food Frontiers.
Review – “The Science Behind NMN – A Stable, Reliable NAD+ Activator”
In-depth examination of NMN’s pharmacokinetics, transport mechanisms, and potential anti-aging effects.
Imai et al. (2025) – “2024 FASEB Scientific Research Conference on NAD+ Biology”
Summary of expert panel discussion on NAD+ pathways, precursor comparisons, and future clinical applications from leading NAD+ researchers.
Meta-Analysis (2024) – “Efficacy of oral NMN supplementation on glucose and lipid metabolism”
Systematic review and meta-analysis of 12 randomized controlled trials examining NMN’s effects on metabolic health.
Healthspan Research – “Do NAD+ Boosters Work? What the Research Says About NR and NMN”
Evidence-based summary of NAD+ biology and current clinical research on NR and NMN for aging and cognition.
Reta (Triple Hormone Agonist) Research
Hope et al. (2025) – “Triple Agonism Based Therapies for Obesity”
Comprehensive review of triple agonist development focusing on GLP-1/GIP/glucagon receptor agonism, mechanisms of action, and clinical trial data. Published in Current Cardiovascular Risk Reports.
Landmark phase 2 trial published in New England Journal of Medicine demonstrating 24.2% mean weight reduction and metabolic improvements with triple agonist therapy in adults with obesity.
Ali et al. (2025) – “Efficacy and safety of retatrutide: systematic review and meta-analysis”
Meta-analysis of three randomized controlled trials (878 patients) comparing triple agonist therapy with placebo, showing superior weight loss and favorable safety profile.
Khoo et al. (2025) – “Retatrutide—A Game Changer in Obesity Pharmacotherapy”
Comprehensive review of retatrutide’s mechanisms, efficacy in type 2 diabetes, obesity, and cardiometabolic benefits. Published in Pharmaceuticals.
Report on TRIUMPH-4 phase 3 trial results showing 28.7% weight loss and improvements in joint pain and physical function in adults with obesity and osteoarthritis.
Springer Nature – “Triple Agonism Based Therapies for Obesity”
Clinical review comparing triple agonist therapy to existing mono- and dual-agonist therapies, discussing development challenges and emerging research directions.
MedStar Health – “Next-Level Obesity and Cardiovascular Care Starts with Clinical Trials”
Overview of next-generation obesity therapies including triple agonist information and ongoing clinical trial programs for cardiometabolic outcomes.
USADA – “BPC-157: Experimental Peptide Creates Risk for Athletes”
Official WADA statement on BPC-157’s prohibited status and lack of human safety/efficacy evidence.
STAT News (2026) – “BPC-157: Miracle Healing Peptide or Hidden Danger?”
Investigative journalism examining BPC-157’s research quality, regulatory status, and safety concerns.
Review (2025) – “Promising Results With NAD Supplementation in Rare Diseases”
Research on NAD+ supplementation in genetic syndromes with premature aging and DNA damage.
Clinical Interpretation and Future Directions
BPC-157: Preclinical Promise
BPC-157 demonstrates compelling potential in preclinical research models. The extensive animal research base provides mechanistic insight into tissue healing pathways and growth factor modulation. As clinical research expands, human data will be essential to establish safety profiles and determine therapeutic relevance.
MOTs-c: Emerging Metabolic Research
MOTs-c represents a novel target for metabolic optimization and age-related disease prevention. Current research focuses on understanding the peptide’s role in mitochondrial function, glucose metabolism, and cellular senescence. Clinical applications continue to be investigated by multiple research groups worldwide.
NMN: Evidence-Based NAD+ Support
NMN has the most extensive human clinical data among peptide compounds discussed in this review. Published trials demonstrate measurable benefits in physical performance metrics, muscle composition, and metabolic parameters. The established safety profile supports continued research in aging populations and metabolic disorders.
Understanding the Evidence Hierarchy
When evaluating emerging peptide therapies, the hierarchy of scientific evidence provides important context:
- NMN/NAD+ Precursors: Multiple published human clinical trials with peer-reviewed results. Established safety data from long-term supplementation studies. Available through regulated dietary supplement pathways.
- BPC-157: Extensive preclinical research base exceeding 540 publications. Limited but growing human clinical research. Available through research chemical suppliers for investigational purposes.
- MOTs-c: Expanding preclinical evidence in metabolic and aging models. Multiple ongoing clinical research programs. Early investigational phase with promising mechanistic data.
The peptide field represents one of the most dynamic areas of biomedical research. As investigation continues across these compounds, advancing our understanding of their mechanisms and clinical applications will refine therapeutic strategies for age-related diseases, metabolic dysfunction, and tissue regeneration.
